Back

Teva To Present New Asthma and COPD Data at the 2017 European Respiratory Society (ERS) International Congress

Teva To Present New Asthma and COPD Data at the 2017 European Respiratory Society (ERS) International Congress

  • New Analyses To Be Presented for Two Respiratory Therapies - CINQAERO®▼ (reslizumab) and DuoResp Spiromax® (budesonide/formoterol fumarate dihydrate)

About Teva

Teva is among the top 15 global pharmaceutical companies globally, delivering high-quality, patient-centric healthcare solutions used by approximately 200 million patients in 60 markets every day. Teva produces a leading innovative treatment for multiple sclerosis and has late-stage development programs for a range of disorders of the central nervous system, including movement disorders, migraine, pain and neurodegenerative conditions. With its European headquarters in Amsterdam, the Netherlands, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a broad range of products in nearly every therapeutic area. Teva draws on its specialty and generics capabilities to seek new ways of addressing unmet patient needs by combining drug development with devices, services and technologies. Teva's net revenues in 2016 were $21.9 billion. For more information, visit www.tevapharm.com.